Impact of Sprint Stair Climbing "Snacks" on Markers of Metabolism and Vascular Function

September 24, 2019 updated by: Jonathan Little, University of British Columbia

Salivary Insulin Profiles Throughout the Day in Healthy Humans

Prolonged sitting has been shown to impair metabolism and vascular function. The overall purpose of this study is to determine if breaking up prolonged (9 hours) of sitting with brief (~20 second) stair climbing exercise "snacks" can improve markers of metabolic control and vascular health in healthy young male participants and in males or females with overweight/obesity who are at risk of insulin resistance. An additional purpose is to determine if saliva insulin can be used as a valid indicator of blood insulin when measured throughout the day in sedentary and active conditions and when diets with different amounts of carbohydrates are consumed.

Study Overview

Study Type

Interventional

Enrollment (Actual)

23

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • British Columbia
      • Kelowna, British Columbia, Canada, V1V 3G1
        • University of British Columbia Okanagan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Lean Group Inclusion Criteria:

Non-smoking

Lean Group Exclusion Criteria:

Diagnosed with diabetes or prediabetes (fasting blood sugar more than 6.0 mmol/l) or any other chronic condition that may impact glucose or insulin levels.

BMI is over 25 kg/m2 Take medications which may affect glucose and insulin levels Allergic to eggs. Smoker Competitive or serious endurance athlete.

Overweight/Obese Group Inclusion Criteria:

Elevated waist circumference (>102 cm for male and >88 cm for female)

Overweight/Obese Group Exclusion Criteria:

Diagnosed with diabetes (fasting blood sugar more than 7.0 mmol/l) Take medications which may affect glucose and insulin levels Allergic to eggs. Smoker Competitive or serious endurance athlete.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High-Carbohydrate Sedentary
Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals)
Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
Experimental: High-Carbohydrate Active
Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals) but will complete 8 stair climbing sprint "snacks" once per hour involving ascending 3 flights of stairs at a vigorous pace (~20 seconds each).
Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint "snack") for a total of 8 active breaks.
Active Comparator: Low-Carbohydrate Sedentary
Participants will remain seated for 9 hours (except for using the restroom) while consuming a low-carbohydrate diet (3 meals)
Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma insulin area under the curve
Time Frame: Measured across 9 hours of each intervention day
The plasma insulin concentration measured by enzyme-linked immunosorbent assay area under the curve will be measured using the trapezoidal rule.
Measured across 9 hours of each intervention day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Saliva insulin area under the curve
Time Frame: Measured across 9 hours of each intervention day
The saliva insulin concentration measured by enzyme-linked immunosorbent assay area under the curve will be measured using the trapezoidal rule.
Measured across 9 hours of each intervention day
Plasma glucose area under the curve
Time Frame: Measured across 9 hours of each intervention day
The plasma glucose concentration measured by hexokinase method area under the curve will be measured using the trapezoidal rule.
Measured across 9 hours of each intervention day
Plasma triglyceride area under the curve
Time Frame: Measured across 9 hours of each intervention day
The plasma triglyceride concentration measured by biochemical assay area under the curve will be measured using the trapezoidal rule.
Measured across 9 hours of each intervention day
Plasma non-esterified fatty acids area under the curve
Time Frame: Measured across 9 hours of each intervention day
The plasma non-esterified fatty acid concentration measured by biochemical assay area under the curve will be measured using the trapezoidal rule.
Measured across 9 hours of each intervention day
Femoral artery flow-mediated dilation
Time Frame: Measured in the morning (time 0 hours) and afternoon (time 8.5 hours) each intervention day
Flow-mediated dilation of femoral artery measured by vascular ultrasound
Measured in the morning (time 0 hours) and afternoon (time 8.5 hours) each intervention day
Cerebrovascular function
Time Frame: Measured in the morning (time 0.5 hours) and afternoon (time 6 hours) each intervention day
Cerebrovascular function measured by transcranial doppler ultrasound
Measured in the morning (time 0.5 hours) and afternoon (time 6 hours) each intervention day
Cognitive function
Time Frame: Measured in the morning (time 0.5 hours) and afternoon (time 6 hours) each intervention day
Cognitive function measured by Computerized Neurocognitive Assessment Software (CNS) Vital Signs test battery
Measured in the morning (time 0.5 hours) and afternoon (time 6 hours) each intervention day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2017

Primary Completion (Actual)

June 30, 2019

Study Completion (Actual)

August 30, 2019

Study Registration Dates

First Submitted

December 11, 2017

First Submitted That Met QC Criteria

December 11, 2017

First Posted (Actual)

December 15, 2017

Study Record Updates

Last Update Posted (Actual)

September 25, 2019

Last Update Submitted That Met QC Criteria

September 24, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • H17-01747

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

We will share individual patient data (de-identified) with researchers upon request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Physical Activity

Clinical Trials on High-Carbohydrate Sedentary

Subscribe